Florida Cancer Specialists & Research Institute (FCS), a recognized leader in value-based oncology care, continues to establish innovative partnerships with payers, embracing alternative payment models to enhance cancer treatment. Building on its successful participation in the Centers for Medicare and Medicaid Innovation’s (CMMI) Oncology Care Model (OCM) pilot program, FCS is pioneering new approaches to improve patient outcomes and reduce healthcare costs.
Image of a doctor and patient discussing treatment options
Building on Success: From OCM to Innovative Partnerships
FCS’s participation in the OCM pilot program provided valuable insights into structuring processes that improve both patient outcomes and the overall cost of care. Dr. Lucio N. Gordan, MD, President & Managing Physician of FCS, notes that the OCM served as a catalyst for the numerous value-based care partnerships and programs the organization currently pursues.
Collaborative Value-Based Care Models: Lowering Costs, Improving Outcomes
Leveraging lessons learned from the OCM, FCS has expanded its value-based care initiatives by collaborating with commercial payers. These partnerships have demonstrated effectiveness in lowering healthcare expenditures while simultaneously enhancing patient support, leading to improved clinical outcomes. A recent FCS case study, “Accountable Provider Organization (APO) Partnership Delivers Quality and Cost-Effective Care,” showcases the positive impact of these collaborative efforts.
Image highlighting collaborative care models in oncology
Expanding Value-Based Care Initiatives: Medicare Advantage and Beyond
FCS has also strengthened its relationships with Medicare Advantage plans and actively participates in enhanced quality plans with Medicare through the Merit-based Incentive Payments System (MIPS). Furthermore, FCS is exploring innovative contracting opportunities, including bundled payment methodologies and capitation models.
Driving Value Through Innovation: Biosimilars, Next-Generation Sequencing, and Enhanced Access
Nathan H. Walcker, Chief Executive Officer of FCS, emphasizes the organization’s commitment to driving value through strategic initiatives such as the utilization of biosimilar drugs, next-generation sequencing, and improved patient access to clinicians. Each program provides opportunities to learn and refine approaches to maximize value for patients.
Continued Commitment to Value-Based Oncology Care
FCS remains dedicated to advancing value-based care initiatives through strategic partnerships and innovative models. Multiple case studies conducted by the practice demonstrate the effectiveness of these models in improving clinical outcomes and reducing healthcare costs.
Conclusion: A Future of Value-Driven Cancer Care
Florida Cancer Specialists & Research Institute is committed to delivering high-quality, cost-effective cancer care through value-based initiatives. By embracing innovative partnerships and exploring cutting-edge treatment strategies, FCS is at the forefront of transforming the landscape of oncology care. For more information on FCS’s value-based care programs, please consult a healthcare professional or visit the FCS website.
